Repigmentation of vitiligo with oral baricitinib

Mumford, Blake P; Gibson, Andrew; Chong, Alvin H

doi:10.1111/ajd.13348

Cited by 24 publications

(23 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Baricitinib, a selective JAK1/2 inhibitor, is effective in treating patients with rheumatoid arthritis and is now widely used in dermatologic conditions such as alopecia areata, atopic dermatitis, and vitiligo. 15 , 26 - 29 Small case studies have reported its effectiveness in treating vitiligo, and a new phase 2 study (NCT04822584) is currently being conducted to evaluate the safety and efficacy of the combination of baricitinib and phototherapy in vitiligo treatment. 15 , 30 In this study, we treated 4 young patients with progressing vitiligo by using oral baricitinib monotherapy.…”

Section: Discussionmentioning

confidence: 99%

“… 15 , 26 - 29 Small case studies have reported its effectiveness in treating vitiligo, and a new phase 2 study (NCT04822584) is currently being conducted to evaluate the safety and efficacy of the combination of baricitinib and phototherapy in vitiligo treatment. 15 , 30 In this study, we treated 4 young patients with progressing vitiligo by using oral baricitinib monotherapy. Among them, 3 patients had vitiligous lesions on the face and neck, and 1 patient had vitiligous lesions on the trunk.…”

Section: Discussionmentioning

confidence: 99%

“…In a case report, a patient suffered from rheumatoid arthritis and vitiligo got much better re-pigmentation after substituting baricitinib for tofacitinib (a JAK1 and JAK3 inhibitor). 15 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro

Dong

Huang

et al. 2022

Dose-Response

View full text Add to dashboard Cite

Objective To evaluate the clinical efficacy and safety of baricitinib, a Janus kinase (JAK) inhibitor, in treating patient with progressing vitiligo, and to further explore the regulation of baricitinib on melanocytes (MCs) in vitro. Methods Four patients with progressing vitiligo were treated with oral baricitinib for a total of 12 weeks. MCs were cultured in vitro and irradiated by high-dose ultraviolet B (UVB, 150mJ/cm2) to make an MC damaged model (MC-Ds). Baricitinib was added at a final concentration of 25 μM. Dopamine staining and NaOH method were used to measure the tyrosinase activity and melanin level, respectively, real-time quantitative polymerase chain reaction (RT-qPCR) was used to measure the mRNA levels of tyrosinase (TYR), tyrosinase-related protein-1 (TRP-1). Results Significant re-pigmentation was observed in the week 12 without obvious side effects. Depigmentation occurred in 2 patients at the 3-month follow-up. Laboratory research found that higher doses of UVB irradiation (150mJ/cm2) could decrease melanin content of MCs, baricitinib (25 μM) could significantly promote tyrosinase activity, melanin content, and TYR, TRP-1 gene expression of MC-Ds. Conclusion Our preliminary study showed that baricitinib was effective and safe in treating progressing vitiligo. Baricitinib could promote tyrosinase activity, melanin content and TYR, TRP1 gene expression of MC-Ds in vitro.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro

Dong

Huang

et al. 2022

Dose-Response

View full text Add to dashboard Cite

show abstract

“…Interestingly, a patient with rheumatoid arthritis and vitiligo showed a reduction in the area of vitiligo lesions after treatment with baricitinib. 20 , 21 …”

Section: Application Of Baricitinib In Dermatologymentioning

confidence: 99%

Application of Baricitinib in Dermatology

Zhang¹,

Qi²,

Dong³

et al. 2022

JIR

View full text Add to dashboard Cite

There are four JAK subtypes: JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). Small molecule Janus tyrosine kinase (JAK) inhibitors can inhibit a variety of pro-inflammatory cytokines. Baricitinib is the first generation of JAK1/2 inhibitor targeting the ATPase of JAK, which blocks the intracellular transmission of cytokines through JAK-STATs. Thus far, it has been approved for the treatment of rheumatoid arthritis (RA); however, an increasing number of studies have suggested that baricitinib can be used to treat dermatological diseases, such as atopic dermatitis (AD), psoriasis, vitiligo, and alopecia areata. Baricitinib can be a new choice for the treatment of dermatological diseases, which cannot be treated with conventional drugs. We reviewed the application, efficacy, side effects, precautions, limitations and prospect of baricitinib in atopic dermatitis, psoriasis, vitiligo and alopecia areata (AA) in recent 5 years including clinical trials and case reports. Among them, the application in the field of alopecia areata is the most encouraging, and we reviewed the mechanism in detail.

show abstract

“…Only one case report has described re-pigmentation in vitiligo lesions treated with baricitinib, a selective JAK1 and JAK2 inhibitor ( 43 ). A 67-year-old man with vitiligo involving the hands and forearms noticed complete re-pigmentation when he substituted his tofacitinib 5 mg twice daily with baricitinib 4 mg daily for the treatment of rheumatoid arthritis ( 37 ). A new phase 2 study (NCT04822584) is currently being conducted to evaluate the safety and efficacy of the combination of baricitinib and phototherapy in vitiligo treatment ( 61 ).…”

Section: The Use Of Jak Inhibitors In Vitiligo Treatmentmentioning

confidence: 99%

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review

Liu

Gao

2021

Front. Immunol.

View full text Add to dashboard Cite

Vitiligo is a multifactorial reversible skin disorder characterized by distinct white patches that result from melanocyte destruction. Activated CXCR3+ CD8+ T cells promote melanocyte detachment and apoptosis through interferon-gamma (IFN-γ secretion and chemokines secreted by keratinocytes through the Janus kinase (JAK)/signal transducer and activator of transcription (STAT)-1 signaling pathway results in further recruitment of CXCR3+ CD8+ T cells and the formation of a positive-feedback loop. JAK inhibitors target the JAK/STAT pathway and are now approved to treat many immune-related diseases. In the treatment of vitiligo, JAK inhibitors, including ruxolitinib, baricitinib, and tofacitinib, are effective, supporting the implication of the IFN-γ-chemokine signaling axis in the pathogenesis of vitiligo. However, more studies are required to determine the ideal dosage of JAK inhibitors for the treatment of vitiligo, and to identify other inflammatory pathways that may be implicated in the pathogenesis of this condition.

show abstract

Repigmentation of vitiligo with oral baricitinib

Cited by 24 publications

References 6 publications

Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro

Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro

Application of Baricitinib in Dermatology

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review

Contact Info

Product

Resources

About